|

Oral MRT-2359 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • Monte Rosa Therapeutics, Inc1

Indications

  • Castration-Resistant Prostate Cancer (CRPC)1
  • Castration-resistant Prostate Cancer1
  • Prostate Cancer (Adenocarcinoma)1
  • Prostate Cancer1
  • Cancer1

Los Angeles, California1 trial

Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

START Los Angeles

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.